HER2 ADCs: GU Malignancies

CME

Emerging HER2-Targeted Antibody–Drug Conjugates in Genitourinary Malignancies

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: April 08, 2024

Expiration: October 07, 2024

Elizabeth R. Plimack
Elizabeth R. Plimack, MD, MS, FASCO

Activity

Progress
1
Course Completed

References

  1. Albarran V, Rosero DI, Chamorro J, et al. Her-2 targeted therapy in advanced urothelial cancer: From monoclonal antibodies to antibody-drug conjugates. Int J Mol Sci. 2022;23. 
  2. Raghav KPS, Loree JM, Kopetz S. PRESSING need of precision care in HER2-positive colorectal cancer: The ELEPHANT in the room. Clin Cancer Res. 2024;30:260-262. 
  3. Kiss B, Wyatt AW, Douglas J, et al. HER2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Sci Rep. 2017;7:42713. 
  4. Ross JS, Wang K, Khaira D, et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016;122:702-711. 
  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer. v.1.2024. nccn.org. Accessed April 4, 2024. 
  6. Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2:e000279. 
  7. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3:224-237. 
  8. Buza N. HER2 testing in endometrial serous carcinoma: Time for standardized pathology practice to meet the clinical demand. Arch Pathol Lab Med. 2021;145:687-691. 
  9. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: penile cancer. nccn.org. Accessed April 4, 2024. 
  10. Wang H, Liu C, Han J, et al. HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue. Oncol Lett. 2012;4:194-198. 
  11. Tan X, Wang Y, Wu Z, et al. The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy. Eur J Cancer. 2023;194:113360. 
  12. Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54:34-44. 
  13. van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778-1789. 
  14. Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875-888. 
  15. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67:173-185. 
  16. Indini A, Rijavec E, Grossi F. Trastuzumab deruxtecan: Changing the destiny of HER2 expressing solid tumors. Int J Mol Sci. 2021;22. 
  17. Galsky M, Del Conte G, Foti S, et al. Primary analysis from DS8201-A-U105: A phase 1b, 2-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium 2023; February 16-18, 2023. Abstract 438.  
  18. O'Donnell PH, Milowsky MI, Petrylak DP, et al. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol. 2023;41:4107-4117. 
  19. Chiang RS, Glover MJ, Khaki AR, Srinivas S. Immunotherapy for urothelial carcinoma: Focus on clinical utility of nivolumab. Onco Targets Ther. 2022;15:1259-1269. 
  20. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium 2023; February 16-18, 2023. Abstract LBA3000.  
  21. Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022;29:1335-1344. 
  22. Sheng X, Wang L, He Z, et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials. J Clin Oncol. 2023:JCO2202912. 
  23. Zhou L, Xu H, Yan X, et al. RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study. Presented at: American Society of Clinical Oncology Annual Meeting 2021; June 4-8, 2021. Abstract 4534.  
  24. Powles T, Yu EY, Iyer G, et al. Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium 2023; February 16-18, 2023. Abstract TPS594.  
  25. Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023;20:558-576. 
  26. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2024. 
  27. Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378.